Stockscreener 앱 받기
16.88
4.26%
0.69
시간 외 거래:
17.00
0.12
+0.71%
전일 마감가:
$16.19
열려 있는:
$16.52
하루 거래량:
1.48M
Relative Volume:
0.64
시가총액:
$1.70B
수익:
$352.57M
순이익/손실:
$-143.01M
주가수익비율:
-9.326
EPS:
-1.81
순현금흐름:
$-153.40M
1주 성능:
-0.88%
1개월 성능:
-16.60%
6개월 성능:
-35.03%
1년 성능:
-30.76%
1일 변동 폭
$15.80
$16.95
1주일 범위
$15.35
$17.27
52주 변동 폭
$13.53
$35.25
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
16.88 | 1.71B | 352.57M | -143.01M | -153.40M | -1.81 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Beam gets FDA orphan drug status for sickle cell disease treatment - Seeking Alpha
Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation - marketscreener.com
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Gra - GuruFocus
Beam Therapeutics Announces Orphan Drug Designation For BEAM-101 - Nasdaq
Beam Therapeutics (BEAM) Gains FDA Orphan Drug Status for Sickle - GuruFocus
Beam Therapeutics’ BEAM-101 receives FDA orphan drug status for SCD treatment - Investing.com
Beam Therapeutics Announces U.S. FDA Orphan Drug - GlobeNewswire
Breakthrough Sickle Cell Treatment BEAM-101 Secures FDA Orphan Drug Status After Strong Trial Results - Stock Titan
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment By Investing.com - Investing.com South Africa
FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy - Insider Monkey
Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment - Investing.com India
FDA Grants Orphan Drug Status to Beam Therapeutics' (BEAM) BEAM-302 | BEAM Stock News - GuruFocus
Beam receives Orphan Drug status for genetic disorder asset BEAM-302 - Seeking Alpha
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com
Beam Therapeutics Scores Dual FDA Wins as Orphan Drug Status Follows Promising AATD Trial Results - Stock Titan
Beam Therapeutics: A Cautious Hold On A Base Editing Pioneer (NASDAQ:BEAM) - Seeking Alpha
Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now - simplywall.st
Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New - GuruFocus
Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New Treatment | BEAM Stock News - GuruFocus
BEAM Therapeutics’ SWOT analysis: base editing biotech stock shows promise amid challenges - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX) - The Globe and Mail
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of “Buy” from Analysts - Defense World
Deutsche Bank AG Has $1.67 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR - Endpoints News
(BEAM) Trading Report - news.stocktradersdaily.com
Beam Therapeutics To Present At RBC Capital Markets Global Conference; Webcast At 11:00 AM ET - Nasdaq
Mercer Global Advisors Inc. ADV Sells 4,568 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Tower Research Capital LLC TRC Sells 5,172 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Beam Therapeutics to Highlight New Data from BEAM-101 Program in - GuruFocus
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress | BEAM Stock News - GuruFocus
Beam Therapeutics to Present Updated Data on BEAM-101 in Sickle Cell Disease at EHA2025 Conference - Nasdaq
Beam Therapeutics to Highlight New Data from BEAM-101 - GlobeNewswire
New Clinical Data Reveals: BEAM-101 Treatment Progress in 17 Sickle Cell PatientsKey Findings Coming - Stock Titan
News: The Latest Clinical Trial Updates from CRISPR Medicine News - CRISPR Medicine News
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust Corp - Defense World
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Stifel Financial Corp - Defense World
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Beam Therapeutics (BEAM) Gains FDA RMAT Designation for BEAM-302 - GuruFocus
Beam : FDA Grants RMAT Designation To BEAM-302 For Alpha-1 Antitrypsin Deficiency Treatment - Nasdaq
FDA grants RMAT status to Beam’s AATD gene therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - Stock Titan
HC Wainwright Issues Positive Forecast for BEAM Earnings - Defense World
FY2025 EPS Estimates for BEAM Cut by Cantor Fitzgerald - Defense World
(BEAM) Investment Report - news.stocktradersdaily.com
Wells Fargo & Company Cuts Beam Therapeutics (NASDAQ:BEAM) Price Target to $70.00 - Defense World
Guggenheim Cuts Beam Therapeutics (NASDAQ:BEAM) Price Target to $55.00 - Defense World
Q2 EPS Forecast for Beam Therapeutics Reduced by Analyst - Defense World
Is Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth? - Yahoo Finance
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.19%
자본화:
|
볼륨(24시간):